Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365511886> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4365511886 endingPage "LB301" @default.
- W4365511886 startingPage "LB301" @default.
- W4365511886 abstract "Abstract Ataxia telangiectasia and Rad3-related (ATR) checkpoint kinase orchestrates DNA damage response and repair pathways stimulated by replicative stresses. Recent studies have established that pharmacological inhibition of ATR is clinically promising. As M1774 is an oral ATR inhibitor in clinical development, we explored the molecular basis by which M1774 induces cancer cell death. As a single agent, we found that M1774 suppresses cancer cell viability at nanomolar concentrations with a potency higher than ceralasertib and berzosertib, but lower than gartisertib (M4344) and elimusertib in the small cell lung cancer (SCLC) cell lines H146, H82, and DMS114. We found that M1774 efficiently suppresses the ATR/CHK1 checkpoints. While M1774 alone induced apoptosis and G2/M cell cycle arrest at micromolar concentrations, at a non-toxic low dose, M1774 enhanced TOP1 inhibitor-mediated cancer cell death by preventing replication arrest and inducing DNA damage detected by EdU and γH2AX staining. Tandem mass tagging (TMT) coupled with mass spectrometry revealed that M1774 combined with SN-38 increases the expression of replication-related proteins (TIPIN, CDC45, TIMELESS, and RPA1) and G2/M-related proteins (PLK1 and CCNB1). To establish the synergistic combinations of M1774 with clinical anticancer DNA damaging agents in preclinical models, we performed experiments in cancer cell lines, patient-derived organoids, and xenograft models. Low doses of M1774 significantly synergized with the clinical TOP1 inhibitor SN-38, the TOP2 inhibitor etoposide, cisplatin, and the PARP inhibitor talazoparib in SCLC cell lines. We also found that M1774 significantly reversed chemoresistance to DNA-damaging agents in cancer cells lacking SLFN11 expression, suggesting that SLFN11 expression can be utilized for combination therapy with M1774 as a biomarker. The synergistic efficacy between M1774 and DNA-damaging agents was confirmed in SCLC patient-derived organoids, colon cancer patient-derived organoids, and H82 SCLC xenografts. Together, these results provide insights into the molecular mechanism and potential combination strategies for M1774 in cancer therapy. Citation Format: Ukhyun Jo, Yasuhiro Arakawa, Astrid Zimmermann, Daiki Taniyama, Makito Mizunuma, Lisa M Jenkins, Suresh Kumar, Frank T Zenke, Yves Pommier. Molecular pharmacology and broad synergy of the novel ATR inhibitor M1774 with DNA damaging anticancer agents [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB301." @default.
- W4365511886 created "2023-04-15" @default.
- W4365511886 creator A5009602767 @default.
- W4365511886 creator A5017046869 @default.
- W4365511886 creator A5021550570 @default.
- W4365511886 creator A5029235997 @default.
- W4365511886 creator A5037267427 @default.
- W4365511886 creator A5042114293 @default.
- W4365511886 creator A5066088814 @default.
- W4365511886 creator A5080236358 @default.
- W4365511886 creator A5080482492 @default.
- W4365511886 date "2023-04-14" @default.
- W4365511886 modified "2023-09-23" @default.
- W4365511886 title "Abstract LB301: Molecular pharmacology and broad synergy of the novel ATR inhibitor M1774 with DNA damaging anticancer agents" @default.
- W4365511886 doi "https://doi.org/10.1158/1538-7445.am2023-lb301" @default.
- W4365511886 hasPublicationYear "2023" @default.
- W4365511886 type Work @default.
- W4365511886 citedByCount "0" @default.
- W4365511886 crossrefType "journal-article" @default.
- W4365511886 hasAuthorship W4365511886A5009602767 @default.
- W4365511886 hasAuthorship W4365511886A5017046869 @default.
- W4365511886 hasAuthorship W4365511886A5021550570 @default.
- W4365511886 hasAuthorship W4365511886A5029235997 @default.
- W4365511886 hasAuthorship W4365511886A5037267427 @default.
- W4365511886 hasAuthorship W4365511886A5042114293 @default.
- W4365511886 hasAuthorship W4365511886A5066088814 @default.
- W4365511886 hasAuthorship W4365511886A5080236358 @default.
- W4365511886 hasAuthorship W4365511886A5080482492 @default.
- W4365511886 hasConcept C105696609 @default.
- W4365511886 hasConcept C121608353 @default.
- W4365511886 hasConcept C134935766 @default.
- W4365511886 hasConcept C143425029 @default.
- W4365511886 hasConcept C153911025 @default.
- W4365511886 hasConcept C182979987 @default.
- W4365511886 hasConcept C185592680 @default.
- W4365511886 hasConcept C190283241 @default.
- W4365511886 hasConcept C2776694085 @default.
- W4365511886 hasConcept C2778239845 @default.
- W4365511886 hasConcept C2779138821 @default.
- W4365511886 hasConcept C29537977 @default.
- W4365511886 hasConcept C31573885 @default.
- W4365511886 hasConcept C502942594 @default.
- W4365511886 hasConcept C54355233 @default.
- W4365511886 hasConcept C552990157 @default.
- W4365511886 hasConcept C55493867 @default.
- W4365511886 hasConcept C82381507 @default.
- W4365511886 hasConcept C86803240 @default.
- W4365511886 hasConcept C96232424 @default.
- W4365511886 hasConceptScore W4365511886C105696609 @default.
- W4365511886 hasConceptScore W4365511886C121608353 @default.
- W4365511886 hasConceptScore W4365511886C134935766 @default.
- W4365511886 hasConceptScore W4365511886C143425029 @default.
- W4365511886 hasConceptScore W4365511886C153911025 @default.
- W4365511886 hasConceptScore W4365511886C182979987 @default.
- W4365511886 hasConceptScore W4365511886C185592680 @default.
- W4365511886 hasConceptScore W4365511886C190283241 @default.
- W4365511886 hasConceptScore W4365511886C2776694085 @default.
- W4365511886 hasConceptScore W4365511886C2778239845 @default.
- W4365511886 hasConceptScore W4365511886C2779138821 @default.
- W4365511886 hasConceptScore W4365511886C29537977 @default.
- W4365511886 hasConceptScore W4365511886C31573885 @default.
- W4365511886 hasConceptScore W4365511886C502942594 @default.
- W4365511886 hasConceptScore W4365511886C54355233 @default.
- W4365511886 hasConceptScore W4365511886C552990157 @default.
- W4365511886 hasConceptScore W4365511886C55493867 @default.
- W4365511886 hasConceptScore W4365511886C82381507 @default.
- W4365511886 hasConceptScore W4365511886C86803240 @default.
- W4365511886 hasConceptScore W4365511886C96232424 @default.
- W4365511886 hasIssue "8_Supplement" @default.
- W4365511886 hasLocation W43655118861 @default.
- W4365511886 hasOpenAccess W4365511886 @default.
- W4365511886 hasPrimaryLocation W43655118861 @default.
- W4365511886 hasRelatedWork W1996366132 @default.
- W4365511886 hasRelatedWork W2014811787 @default.
- W4365511886 hasRelatedWork W2077569993 @default.
- W4365511886 hasRelatedWork W2081809884 @default.
- W4365511886 hasRelatedWork W2082054147 @default.
- W4365511886 hasRelatedWork W2116193195 @default.
- W4365511886 hasRelatedWork W2273685989 @default.
- W4365511886 hasRelatedWork W2372244207 @default.
- W4365511886 hasRelatedWork W2489771376 @default.
- W4365511886 hasRelatedWork W2611411691 @default.
- W4365511886 hasVolume "83" @default.
- W4365511886 isParatext "false" @default.
- W4365511886 isRetracted "false" @default.
- W4365511886 workType "article" @default.